Target Name: OGN
NCBI ID: G4969
Review Report on OGN Target / Biomarker Content of Review Report on OGN Target / Biomarker
OGN
Other Name(s): OGN variant 3 | OIF | Mimecan (isoform 2) | OGN variant 1 | corneal keratan sulfate proteoglycan | OTTHUMP00000021651 | Mimecan proteoglycan | OTTHUMP00000063691 | MIME_HUMAN | OG | Osteoglycin, transcript variant 1 | SLRR3A | osteoglycin | DKFZp586P2421 | Osteoglycin preproprotein | OTTHUMP00000021650 | Osteoglycin | Osteoglycin, transcript variant 3 | Osteoinductive factor | Mimecan | mimecan proteoglycan | Corneal keratan sulfate proteoglycan | osteoinductive factor

OGN: A Potential Drug Target for Neurodegenerative Diseases

OGN (Ogden family of neurotrophic factors) is a protein that is expressed in the nervous system and has been shown to play a role in the development and progression of neurodegenerative diseases. OGN has also been identified as a potential drug target and biomarker for a variety of neurological conditions.

OGN is a member of the Ogden family of neurotrophic factors, which are a group of proteins that are known for their ability to promote the survival and growth of neurons. The Ogden family of neurotrophic factors includes several different proteins, including OGN, which was identified as a potential drug target and biomarker for a variety of neurological conditions.

One of the key functions of OGN is its ability to stimulate the growth and survival of neurons. This is accomplished through the interaction of OGN with its downstream target, TrkB. TrkB is a protein that is known for its role in the intracellular signaling pathway known as the TOR signaling pathway. This pathway is involved in a variety of cellular processes, including cell growth, metabolism, and stress resistance.

OGN has also been shown to play a role in the regulation of neuronal excitability. This is accomplished through its ability to interact with the voltage-dependent ion channel, VDCC, which is involved in the regulation of neuronal action potential formation.

OGN has also been shown to be involved in the regulation of neurotransmitter release and neurotransmission signaling. This is accomplished through its interaction with the neurotransmitter receptor, NTRK1. NTRK1 is a protein that is involved in the regulation of neurotransmitter release and neurotransmission, and is also known as the GABA receptor.

In addition to its role in neurotrophic factors and neurotransmission, OGN has also been shown to be involved in the regulation of inflammation and cellular stress. This is accomplished through its interaction with the transcription factor Nrf2 and the inflammatory responder PD-1.

OGN has also been shown to be involved in the regulation of cell survival and apoptosis. This is accomplished through its interaction with the apoptosis signal transduction factor BAX and the apoptosis regulatory protein CHOP.

OGN has also been shown to be involved in the regulation of the blood-brain barrier. This is accomplished through its interaction with the blood-brain barrier tight-junction protein, JBJ1.

OGN has also been shown to be involved in the regulation of neurogenesis and neuroplasticity. This is accomplished through its interaction with the neurogenesis factor, Sox2.

In conclusion, OGN is a protein that is involved in a variety of cellular processes that are important for the development and progression of neurodegenerative diseases. OGN has also been identified as a potential drug target and biomarker for a variety of neurological conditions, including Alzheimer's disease , Parkinson's disease, and other neurodegenerative disorders. Further research is needed to fully understand the role of OGN in the development and progression of neurodegenerative diseases, as well as its potential as a drug target and biomarker.

Protein Name: Osteoglycin

Functions: Induces bone formation in conjunction with TGF-beta-1 or TGF-beta-2

The "OGN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OGN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OGT | OIP5 | OIP5-AS1 | OIT3 | OLA1 | OLA1P1 | OLAH | OLFM1 | OLFM2 | OLFM3 | OLFM4 | OLFML1 | OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1